Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 4, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 4, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 178 Common Stock at $512.49 ($91,222) on August 4, 2026; holds 333,765 after (Indirect).
  • Open-market sale: disposed of 182 Common Stock at $513.39 ($93,438) on August 4, 2026; holds 333,583 after (Indirect).
  • Open-market sale: disposed of 675 Common Stock at $514.43 ($347,238) on August 4, 2026; holds 332,908 after (Indirect).
  • Open-market sale: disposed of 605 Common Stock at $515.50 ($311,877) on August 4, 2026; holds 332,303 after (Indirect).
  • Open-market sale: disposed of 2,456 Common Stock at $516.59 ($1,268,754) on August 4, 2026; holds 329,847 after (Indirect).
  • Open-market sale: disposed of 3,142 Common Stock at $517.50 ($1,625,972) on August 4, 2026; holds 326,705 after (Indirect).
  • Open-market sale: disposed of 1,446 Common Stock at $518.40 ($749,601) on August 4, 2026; holds 325,259 after (Indirect).
  • Open-market sale: disposed of 517 Common Stock at $519.50 ($268,581) on August 4, 2026; holds 324,742 after (Indirect).
  • Open-market sale: disposed of 299 Common Stock at $520.49 ($155,626) on August 4, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on August 4, 2026; holds 208,410 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,912,310 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-04Option exercise/conversionCommon Stock9,500$135$1.3M333,943
2026-08-04Open-market saleCommon Stock178$512$91.2K333,765
2026-08-04Open-market saleCommon Stock182$513$93.4K333,583
2026-08-04Open-market saleCommon Stock675$514$347.2K332,908
2026-08-04Open-market saleCommon Stock605$515$311.9K332,303
2026-08-04Open-market saleCommon Stock2,456$517$1.3M329,847
2026-08-04Open-market saleCommon Stock3,142$517$1.6M326,705
2026-08-04Open-market saleCommon Stock1,446$518$749.6K325,259
2026-08-04Open-market saleCommon Stock517$519$268.6K324,742
2026-08-04Open-market saleCommon Stock299$520$155.6K324,443
2026-08-04Option exercise/conversionStock Option9,500——208,410

Key Dates

DateDescription
2026-08-04Option exercise/conversion (9,500 shares)
2026-08-04Open-market sale (178 shares)
2026-08-04Open-market sale (182 shares)
2026-08-04Open-market sale (675 shares)
2026-08-04Open-market sale (605 shares)
2026-08-04Open-market sale (2,456 shares)
2026-08-04Open-market sale (3,142 shares)
2026-08-04Open-market sale (1,446 shares)
2026-08-04Open-market sale (517 shares)
2026-08-04Open-market sale (299 shares)
2026-08-04Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.